For research use only. Not for therapeutic Use.
Glasdegib（Cat No.:I000401）is an oral inhibitor of the Hedgehog signaling pathway, specifically targeting the Smoothened (SMO) receptor. It is used in combination with low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in elderly patients or those unable to undergo intensive chemotherapy. By inhibiting the Hedgehog pathway, Glasdegib disrupts the survival and proliferation of leukemic stem cells, slowing disease progression. Its targeted mechanism offers a novel approach for AML treatment, providing an option for patients with limited tolerance to conventional therapies.
| Catalog Number | I000401 |
| CAS Number | 1095173-27-5 |
| Synonyms | 1-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-3-(4-cyanophenyl)urea |
| Molecular Formula | C21H22N6O |
| Purity | 98% |
| Target | SMO |
| Target Protein | |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | 4 nM (Smo) |
| IUPAC Name | 1-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-3-(4-cyanophenyl)urea |
| InChI | InChI=1S/C21H22N6O/c1-27-11-10-16(24-21(28)23-15-8-6-14(13-22)7-9-15)12-19(27)20-25-17-4-2-3-5-18(17)26-20/h2-9,16,19H,10-12H2,1H3,(H,25,26)(H2,23,24,28)/t16-,19-/m1/s1 |
| InChIKey | SFNSLLSYNZWZQG-VQIMIIECSA-N |
| SMILES | CN1CC[C@H](C[C@@H]1C2=NC3=CC=CC=C3N2)NC(=O)NC4=CC=C(C=C4)C#N |
| Reference | [1]. Sadarangani A, et al. GLI2 inhibition abrogates human leukemia stem cell dormancy. J Transl Med. 2015 Mar 21;13:98. |
